

Ref. No: 0306
Date: 05/10/23
Subject: Biologic Medicines in Gastroenterology

REQUEST

I have a Freedom of Information query regarding the use of Biologic medicines in Gastroenterology. Could you please answer the following two questions:

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

- 1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

Treatment	No. Patients
Adalimumab - Humira	9
Adalimumab Biosimilar	191
Filgotinib	<5
Golimumab	<5
Infliximab - Remicade	<5
Infliximab Biosimilar	308
Mirikizumab	0
Ozanimod	0
Risankizumab	0
Tofacitinib	22
Upadacitinib	<5
Ustekinumab	167
Vedolizumab	122

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

Treatment	No. Patients
Adalimumab - Humira	0
Adalimumab Biosimilar	69
Filgotinib	<5
Golimumab	<5
Infliximab - Remicade	0
Infliximab Biosimilar	71
Mirikizumab	0
Ozanimod	0
Risankizumab	0
Tofacitinib	16
Upadacitinib	<5
Ustekinumab	29
Vedolizumab	44

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.